MedinCell S.A. (MDCLF)
USD 6.98
(0.0%)
USD 6.98
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -20.97 Million EUR | 12.69% |
| 2023 | -24.02 Million EUR | -0.89% |
| 2022 | -23.81 Million EUR | -52.59% |
| 2021 | -15.6 Million EUR | 19.24% |
| 2020 | -19.32 Million EUR | -24.54% |
| 2019 | -15.51 Million EUR | -110.3% |
| 2018 | -7.37 Million EUR | -105.57% |
| 2017 | -3.58 Million EUR | -952.49% |
| 2016 | 421 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -10.16 Million EUR | -126.95% |
| 2024 Q1 | -4.47 Million EUR | 69.07% |
| 2024 Q3 | -5.99 Million EUR | 41.05% |
| 2024 FY | -23.88 Million EUR | 0.6% |
| 2024 Q4 | -5.99 Million EUR | -0.11% |
| 2023 Q2 | -13.35 Million EUR | -129.3% |
| 2023 Q4 | -14.47 Million EUR | -134.03% |
| 2023 Q1 | -5.82 Million EUR | 59.48% |
| 2023 FY | -24.02 Million EUR | -0.89% |
| 2023 Q3 | -6.18 Million EUR | 53.69% |
| 2022 Q1 | -5.6 Million EUR | 37.27% |
| 2022 FY | -23.81 Million EUR | -52.59% |
| 2022 Q4 | -14.37 Million EUR | -128.31% |
| 2022 Q3 | -6.29 Million EUR | 54.26% |
| 2022 Q2 | -13.76 Million EUR | -145.48% |
| 2021 Q1 | -4.06 Million EUR | 66.98% |
| 2021 Q4 | -8.94 Million EUR | -65.64% |
| 2021 Q3 | -5.39 Million EUR | 46.55% |
| 2021 Q2 | -10.1 Million EUR | -148.43% |
| 2021 FY | -15.6 Million EUR | 19.24% |
| 2020 FY | -19.32 Million EUR | -24.54% |
| 2020 Q2 | -10.05 Million EUR | -150.27% |
| 2020 Q3 | -5.56 Million EUR | 44.62% |
| 2020 Q4 | -12.31 Million EUR | -121.06% |
| 2020 Q1 | -4.01 Million EUR | 9.61% |
| 2019 Q3 | -4.44 Million EUR | -34.35% |
| 2019 FY | -15.51 Million EUR | -110.3% |
| 2019 Q2 | -3.3 Million EUR | 0.0% |
| 2019 Q1 | -3.3 Million EUR | -131.53% |
| 2019 Q4 | -4.44 Million EUR | 0.0% |
| 2018 Q3 | -1.42 Million EUR | 30.45% |
| 2018 Q4 | -1.42 Million EUR | 0.0% |
| 2018 FY | -7.37 Million EUR | -105.57% |
| 2018 Q1 | -2.05 Million EUR | 0.0% |
| 2018 Q2 | -2.05 Million EUR | 0.0% |
| 2017 FY | -3.58 Million EUR | -952.49% |
| 2016 FY | 421 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 70.778% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 526.812% |
| SQZ Biotechnologies Company | -75.82 Million USD | 72.335% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -17.538% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 125.628% |
| Mesoblast Limited | -84.14 Million USD | 75.071% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1265.647% |
| Genus plc | 6.4 Million USD | 427.766% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 315.315% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -2152.249% |
| Marizyme, Inc. | -34.08 Million USD | 38.46% |
| ContraFect Corporation | -56.88 Million USD | 63.126% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -151.222% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -360.555% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1396.229% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -635.904% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -662.567% |
| MultiCell Technologies, Inc. | -722.81 USD | -2902045.792% |
| Accustem Sciences Inc. | -3.74 Million USD | -459.921% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 64.44% |
| EV Biologics, Inc. | -483.06 Thousand USD | -4242.507% |
| Q BioMed Inc. | -3.44 Million USD | -508.803% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 692.571% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -5284.655% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -698.357% |
| Biomind Labs Inc. | -1 Million USD | -1977.747% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -329.897% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -215.538% |
| Skye Bioscience, Inc. | -13.67 Million USD | -53.433% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -955.989% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -69935.39% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -315.84% |
| IMV Inc. | -38.67 Million USD | 45.756% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -32.182% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -985.423% |
| GB Sciences, Inc. | -1.42 Million USD | -1376.724% |
| Alpha Cognition Inc. | -9.7 Million USD | -116.133% |
| HST Global, Inc. | -140.9 Thousand USD | -14787.124% |
| CSL Limited | 3.7 Billion USD | 100.567% |
| Halberd Corporation | -75.05 Thousand USD | -27850.7% |
| Enzolytics Inc. | -2.14 Million USD | -876.219% |
| Resverlogix Corp. | -12.74 Million USD | -64.538% |
| Affymax, Inc. | -15.04 Million USD | -39.419% |
| SYBLEU INC | -149.18 Thousand USD | -13961.536% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -562.096% |
| argenx SE | -425.04 Million USD | 95.065% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 62.209% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1909.291% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1228.2% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -516.068% |
| AVAX Technologies, Inc. | 6.69 Million USD | 413.423% |
| Zenith Capital Corp. | -8.94 Million USD | -134.563% |
| Genscript Biotech Corporation | -415.79 Million USD | 94.955% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -120312.146% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -754.35% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -12130.807% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 61.841% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -623.033% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2031.694% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1025.152% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1570.143% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -946.361% |
| BioStem Technologies, Inc. | -7.77 Million USD | -169.663% |
| ONE Bio Corp. | 13.68 Million USD | 253.323% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -11458.531% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1470.804% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1764.778% |
| Agentix Corp. | -1.37 Million USD | -1429.208% |
| LadRx Corporation | -3.82 Million USD | -448.615% |
| Cell Source, Inc. | -4.32 Million USD | -384.979% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4948.871% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2953.643% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2953.643% |
| NovAccess Global Inc. | -2.46 Million USD | -750.387% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -618.527% |
| Itoco Inc. | -919.14 Thousand USD | -2182.242% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -394.926% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1774.62% |
| Kadimastem Ltd | -3.04 Million USD | -589.976% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -7914.871% |
| CytoDyn Inc. | -18.05 Million USD | -16.165% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -83241.279% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3682.707% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -9431.621% |
| Qrons Inc. | -643.67 Thousand USD | -3158.933% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -3614.564% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -840.724% |
| Rebus Holdings, Inc. | -664 Thousand USD | -3059.187% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1054.918% |
| International Stem Cell Corporation | -663 Thousand USD | -3063.952% |
| Bioxytran, Inc. | -3.82 Million USD | -449.115% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -39749.924% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -103031.76% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 42.158% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1196.477% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2750.775% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -574.285% |
| Neutra Corp. | -229.48 Thousand USD | -9040.863% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -19.602% |
| PureTech Health plc | -146.19 Million USD | 85.652% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 2.392% |
| IXICO plc | -1.43 Million USD | -1359.777% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -121.02% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 82.778% |
| CSL Limited | 3.81 Billion USD | 100.55% |
| Cellectis S.A. | -108.85 Million USD | 80.73% |